About JAMA Oncology
Mary L. (Nora) Disis, MD
Editor
JAMA Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
Journal Frequency and Access. JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives over 2.4 million online visits annually and more than 3.6 million article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program.
Editorial Information. The journal’s acceptance rate is 13%. The median time to first decision is 2 days, and 43 days with review. The journal's Impact Factor is 31.8, one of the highest ranking among oncology journals. All articles are published online first. Additional information on the types of articles published and editorial policies is available in the journal's Instructions for Authors.
Editorial Team. The founding Editor in Chief of JAMA Oncology is Mary L. (Nora) Disis, MD. Dr Disis is director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health. She is also associate dean of the UW School of Medicine, dean of Research and Graduate Education, associate dean of Translational Science, Helen B. Slonaker Endowed Professor for Cancer Research, professor of Medicine and Oncology, and adjunct professor of Obstetrics & Gynecology and Pathology. For a complete listing of the journal's Editors and Editorial Board, see Editors and Publishers.
Mission Statement. JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
JAMA Oncology
ISSN 2374-2437 (Print)
ISSN 2374-2445 (Online)
Back to top
Why Publish in JAMA Oncology?
JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.
Impact and Reach
- Impact Factor of 31.8, one of the highest ranking among oncology journals
- Over 2.4 million annual visits to the JAMA Oncology website; more than 3.6 million article views and downloads
- International authors: 53% of submissions come from outside the United States
- Extensive press coverage, with over 4,800 media mentions in 2021 in outlets such as The Washington Post, CNN, Forbes, and Reuters
- Top Altmetric scores—JAMA Oncology published 19 of the top 50 articles among oncology journals
- Number of citations, Altmetric score, page views, and PDF downloads tracked for your published article
- Broad reach through related commentary, author audio interviews, podcasts, email alerts, social media, multimedia, and more than 67,000 followers on Twitter and Facebook
Prompt Decisions and Rapid Publication Timelines
- Highly selective peer review and editorial evaluation, with 13% acceptance rate for all submissions
- Median time to first decision: 2 days without external peer review; 43 days with review
- Online First publication of all major articles
- Coordination with meeting presentation: Opportunity to publish new research simultaneously with your presentation
Author Service
- User-friendly manuscript submission system and process
- Prompt, expert review and consideration from our experienced editors
- Highest standards followed to improve your accepted manuscript’s accuracy, reliability, and readability
- CME credit available for lead authors who publish in JAMA Oncology
- Opportunity for your work to be augmented with expert illustration, interactive features, video, audio, and visual abstract
- Free public access: All research articles are free 12 months after publication on the journal's website
- Open access: Authors of research articles may elect to pay for immediate open access on the day of publication
- Direct deposit to PubMed Central: All research articles deposited directly in PubMed Central (PMC) for authors
- Online extras: Ability to post supplemental content online and download your article’s tables and figures as PowerPoint slides
- The JAMA Network advantage: Authors of papers not accepted by JAMA Oncology may have the option to have their papers and reviewers' comments automatically referred to one of the JAMA Network specialty journals and/or JAMA Network Open
- Dedicated media team to promote your article to the news media and on social media
JAMA Network journals welcome manuscript submissions on diversity, equity, and inclusion. For example, see the Health Disparities Topic Collection and the list of articles on race, racism, and racial/ethnic disparities/inequities published during the last 5 years here.
For more information, see JAMA Oncology Instructions for Authors. Submit your manuscript at https://manuscripts.jamaonc.com.
Back to top
Updated June 2022